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Abstract 
Background: Candida albicans is the most common pathogenic fungus isolated in bloodstream infections in hos‑
pitalized patients, and candidiasis represents the fourth most common infection in United States hospitals, mostly 
due to the increasing numbers of immune‑ and medically‑compromised patients. C. albicans has the ability to form 
biofilms and morphogenetic conversions between yeast and hyphal morphologies contribute to biofilm develop‑
ment and represent an essential virulence factor. Moreover, these attached communities of cells are surrounded by a 
protective exopolymeric matrix that effectively shelters Candida against the action of antifungals. Because of dismal 
outcomes, novel antifungal strategies, and in particular those targeting biofilms are urgently required. As fungi are 
eukaryotic, research and development of new antifungal agents has been difficult due to the limited number of selec‑
tive targets, also leading to toxicity.
Results: By microwave‑assisted techniques we obtained pure 1 nm spherical silver nanoparticles ideal for their 
potential biological applications without adding contaminants. A phenotypic assay of C. albicans demonstrated a 
potent dose‑dependent inhibitory effect of silver nanoparticles on biofilm formation, with an IC50 of 0.089 ppm. Also 
silver nanoparticles demonstrated efficacy when tested against pre‑formed C. albicans biofilms resulting in an IC50 of 
0.48 ppm. The cytotoxicity assay resulted in a CC50 of 7.03 ppm. The ultrastructural differences visualized under SEM 
with silver nanoparticles treatment were changes in the surface appearance of the yeast from smooth to rough thus 
indicating outer cell wall damage. On the fungal pre‑formed biofilm true hyphae was mostly absent, as filamentation 
was inhibited. TEM measurement of the cell‑wall width of C. albicans after treatment resulted in significant enlarge‑
ment (206  ±  11 nm) demonstrating membrane permeabilization.
Conclusions: Our results demonstrate that silver nanoparticles are potent inhibitors of C. albicans biofilm formation. 
SEM observations are consistent with an overall loss of structure of biofilms mostly due to disruption of the outer cell 
membrane/wall and inhibition of filamentation.TEM indicates the permeabilization of the cell wall and subsequent 
disruption of the structural layers of the outer fungal cell wall. The anti‑biofilm effects are via cell wall disruption.
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Background
Candida albicans (C. albicans) is a pleomorphic fun-
gus which is a normal commensal of the gastrointestinal 
microbiota in healthy individuals; however, as an oppor-
tunistic pathogen, C. albicans is the most common etio-
logical agent of candidiasis, now the fourth most frequent 
infection in the US hospitals [1], mostly due to the 
increasing numbers of susceptible compromised patients 
that are at risk of this systemic fungal infection [2–4]. 
One important factor that contributes to the pathogen-
esis of candidiasis is biofilm formation, as C. albicans has 
the ability to form biofilms on both inert and biological 
surfaces. In particular, indwelling prosthetic devices and 
catheters possess an optimal surface for Candida’s bio-
film formation [5] and C. albicans is one of the most com-
mon pathogens isolated in catheter-related blood stream 
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infections resulting in high morbidity and mortality rates 
[2]. These biofilms are typically surrounded by an exopol-
ymeric substance (EPS) matrix [6] which effectively 
shelters the fungal cells against adverse environmental 
conditions, including host defense mechanisms and the 
action of antifungals [7]. Moreover, Candida biofilm for-
mation is clinically important as sessile communities of 
yeasts are the reservoirs originating the spread of fungal 
infections [8]. It has been demonstrated that morphology 
(yeast to hypha morphogenetic conversions) plays a very 
important role in biofilm formation and also represents a 
critical virulence factor [9]. The functions of filamentous 
hyphae are adhesion, invasion to biotic or abiotic surface, 
reinforcement of the fungal colony, nourishment and the 
construction of a tridimensional designed formation [10].
Research and development of new antifungal agents 
is complicated by the paucity of selective targets, since 
fungi are eukaryotic cells. This fact is also responsible 
for high levels of toxicity displayed by some of the cur-
rent antifungals, particularly the polyenes and to a lesser 
extent the azoles [11]. In addition, drug resistance of C. 
albicans against antifungals such as azoles and echino-
candins represents an increasing problem. Formation of 
biofilms further complicates treatment, as sessile cells 
within these biofilms have the ability to resist drug con-
centrations even 1000-fold higher than the IC50 reported 
for the planktonic yeasts [6, 12]. Together, all these fac-
tors combined are responsible for clinical failures and 
high mortality in patients with invasive candidiasis [13]. 
Therefore, novel antifungal and antibiofilm drugs against 
these unmanageable infections are urgently needed [7, 
11].
With the advances on Nanotechnology, silver nano-
particles (AgNPs) have demonstrated to be broad-spec-
trum bactericidal [14], virucidal [15–17] and fungicidal 
[18–20]. In recent studies, AgNPs have also proven its 
efficacy against C. albicans [21–24] by disrupting the 
membrane potential and forming pores causing ion leak-
age and other materials [20], inducing apoptosis [19] 
and causing ultrastructural changes [18]. In the present 
study we describe the potent activity displayed by AgNPs 
against C. albicans biofilms and report on the resulting 
ultrastructural changes, both at the cellular level and on 
the overall biofilm structure. In this article we describe 
the synthesis of pure positively charged AgNPs with-
out added chemicals, and more importantly, the AgNPs 
effects on inhibition of filamentation and biofilm forma-
tion of C. albicans.
Results and discussion
Generation and characterization of AgNPs
AgNPs were prepared in the laboratory by microwave-
assisted techniques that have the advantage to achieve fast 
heating and reaction completion to produce large-scale 
metal nanoparticles. This technique is a good alternate 
methodology to synthesize metallic nanoparticles obtain-
ing an efficient control of nanoparticles size distribution 
(Additional file  1), and more importantly for biological 
purposes as it does not involve the handling of potentially 
contaminants or cytotoxic reducing agents [25]. Through-
out the synergy of microwave-reactor methodology 
applied to AgNO3 in the reaction process, reduction takes 
place producing reducing species eliminating the require-
ment of additional reductors, consequently excluding fur-
ther contamination sources [26]. With this methodology 
the reaction can be regulated throughout the control of 
temperature, applied power and reaction time, thereby 
leading to high-yielding, clean, scalable reactions and 
precise size distributions of AgNPs without contami-
nant on biological tests [26]. The Zeta potential value 
increased with time from −2.9 to +13.4 mV over a 120 h 
time period. This shift to positive Zeta potential demon-
strates the adsorption of cations onto particles from the 
solution tested [27]. This Zeta potential result suggests 
that our AgNPs become positively charged, leading to 
their aggregation and enlargement over time. In addi-
tion, we used Transmission Electron Microscopy (TEM) 
and Scanning Electron Microscopy (SEM) techniques 
for the initial characterization of the silver nanoparticles. 
TEM was used to directly visualize the size of the result-
ing AgNPs. As shown in Fig.  1, we determined that the 
AgNPs prepared by this method have a size distribution 
of 1 nm in average size, with also a narrow size distribu-
tion. Thus, both the size and surface charge characteris-
tics of the resulting nanoparticles are considered ideal for 
their potential therapeutic applications [17, 28].
The silver nanoparticles were also characterized on the 
Candida’s biofilm by SEM and Energy-Dispersive X-ray 
Spectroscopy (EDS), at a voltage of 20 kV in a Hitachi S-5500 
SEM (Additional file 2) and also with an EDAX Apollo XL 
SDD detector EDX spectroscopy (Mahwah, NJ, USA) (Fig. 2) 
demonstrating the presence of silver inside and also on the 
outer CW of the yeast cell by TEM after 24 h incubation.
Inhibitory effects of AgNPs against C. albicans biofilms
As mentioned before, biofilm formation by C. albicans 
complicates treatment of these infections, as sessile 
cells within the biofilms display high levels of resistance 
against most clinically-used antifungals [11, 29]. Thus, 
there is an urgent need for novel approaches for the pre-
vention and treatment of biofilm-associated candidiasis 
[11]. In recent years there has been increased interest in 
the utilization of metal, and in particular silver nanopar-
ticles for the treatment of microbial infections [14, 23, 
30], including those associated with a biofilm etiology 
[31, 32]. Thus, in these studies we used a model of biofilm 
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Fig. 1 a TEM micrograph of AgNPs showed spherical shape nanoparticles. b Log‑normal size distribution histogram shows the average AgNP size 
as being approximately 1 nm
Fig. 2 EDS spectra of silver signal 1 inside the yeast cell and 2 on the outer CW. TEM micrograph shows distribution of AgNPs inside the planktonic 
cell and also on the surface of the outer CW after 24 h incubation. EDS spectra of silver nanoparticles demonstrate the presence of elemental silver 
signal in the sample
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formation on the wells of microtiter plates in order to 
examine the inhibitory effects of the AgNPs against C. 
albicans, both for the inhibition of biofilm formation, 
as well as for their activity against pre-formed biofilms. 
Results indicated a dose-dependent and potent inhibitory 
effect of AgNPs on biofilm formation, with a calculated 
IC50 of 0.089  ppm (Fig.  3a). AgNPs also demonstrated 
efficacy when tested against pre-formed C. albicans 
biofilms; although, as expected, activity was detected at 
higher concentrations than those required to inhibit bio-
film formation, resulting in a calculated IC50 of 0.48 ppm 
(Fig. 3b). Importantly, the concentrations of AgNPs dis-
playing effects against C. albicans biofilms are much 
lower than those at which they demonstrate toxicity, as 
measured by a standard cytotoxicity assay using human 
hepatocellular carcinoma (HepG2) cells, resulting in a 
CC50 of 7.03 ppm (Fig. 3c), thereby indicating therapeutic 
potential.
Fig. 3 Phenotypic Assays on Biofilm inhibition by AgNPs. a Different AgNPs concentrations in two‑fold serial dilutions were added to C. albi-
cans cells. The IC50 values for inhibition of biofilm formation were calculated as AgNPs 0.089 ppm (b) AgNPs was also added to preformed (24 h) bio‑
films. The IC50 values for pre‑formed biofilm reduction were calculated as AgNPs 0.48 ppm. All experiments were performed in duplicate on three 
separate occasions. Results represent the means ± standard deviations (SD). c The cytotoxic concentration 50 % (CC50) of AgNPs was measured in 
HEPG2 cell line. The experiments were performed in triplicate, and the results are presented as the mean ± SE. The CC50 values for cell toxicity were 
calculated as AgNPs 7.08 ppm
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Ultrastructural analysis of planktonic C. albicans cells 
after treatment with AgNPs utilizing SEM
The SEM images a sample by scanning across the speci-
men’s surface with a high-energy beam of electrons, it is 
capable of imaging at a considerably enhanced  resolu-
tion  than light microscopes and possesses an improved 
depth of field on the fungal surface and overall biofilm 
topology [33]. With this SEM technique the morpholo-
gies of cells within the biofilms were studied, both in the 
absence and in the presence of AgNPs treatment. The 
ultrastructural differences readily visualized under SEM 
with AgNPs 0.0089  ppm treatment were major changes 
in the surface appearance from smooth (Fig. 4a) to rough 
(Fig. 4b), thus indicating outer CW damage.
Visualization of fungal biofilms by SEM
Under biofilm-growing conditions, cultures were 
treated with AgNPs at a concentration of 0.0089  ppm 
(Fig.  3) during 24  h. As a result we observed scarce 
biofilms, which were composed mostly of yeast cells 
and few filamentous forms. True hyphae were mostly 
absent from these biofilms, as shown in Fig.  5b, d, 
treatment with AgNPs was able to inhibit filamentation 
and subsequent biofilm formation. This is important as 
both filamentation and development of biofilms repre-
sent two of the main virulence factors of Candida spe-
cies [11].
Visualization of fungal pre‑formed biofilms by SEM
SEM was also used to examine the effect of AgNPs at 
a concentration of 0.48  ppm, previously determined to 
be effective by the XTT-reduction assay against pre-
formed biofilms (after 24 h incubation). The correspond-
ing images show that the resulting biofilms show scarce 
cells, which were composed mostly of yeast cells with 
few pseudohyphae or true hyphae as observed in Fig. 6b 
as opposed to the pre-formed biofilm in the absence of 
nanoparticles treatment, which showed a characteristic 
dense network of hyphae and yeast cells (Fig. 6a).
Importantly, these mature biofilms are encased within 
a self-produced protective extracellular matrix (ECM) 
which also imparts most of its resistance properties 
[34, 35]. Interestingly we were able to document the 
presence of AgNPs on the surface of the EPS. As in the 
case of conventional antifungals, these ECM may also 
contribute to the reduced susceptibility of preformed 
biofilms against AgNPs as compared to their efficient 
ability to inhibit the formation of biofilms (Fig.  7b-2), 
the EDS for silver signal on the biofilm was performed 
(Additional file 2).
Ultrastructural analysis of the interaction between AgNPs 
and planktonic C. albicans cells using TEM
Recently, AgNPs have also proven its efficacy against C. 
albicans [21–24] by disturbing the membrane poten-
tial and creating pores therefore provoking ion leakage 
and other materials [20], generating apoptosis [19], and 
showing ultrastructural changes [18]. Therefore we uti-
lized an atomic resolution analytical microscope (JEM-
ARM200F) that achieves a scanning transmission image 
(STEM-HAADF) resolution of 80 pm, one of the highest 
for a Cs corrected TEM [36]. This TEM technique was 
employed to visualize the effects of AgNPs on the ultras-
tructure of C. albicans (Fig. 8). As seen in Fig. 8a, fungal 
cells grown in the absence of AgNPs displayed well-con-
served morphological features, with a typical and dis-
tinctive cytoplasmic membrane and cell-wall. In stark 
contrast, C. albicans cells exposed to AgNPs for 24  h 
(0.089 ppm) were generally enlarged, with alterations in 
the cell membrane and cell wall, which had increased 
in thickness and lost its characteristic electron-dense 
appearance.
Fig. 4 SEM images of planktonic C. albicans cells treated with AgNPs. a Yeasts without treatment show a smooth surface on the CW and b yeast 
after treatment, the white arrow point at rough outer CW. After 24 h incubation and treatment with AgNPs 0.089 ppm
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The cell wall is essential to nearly every aspect of the 
biology and pathogenicity of fungi, with pivotal functions 
in adhesion properties and morphogenetic conversions 
[37]. In C. albicans the cell wall is composed mostly of 
glucans, chitin and mannoproteins. The cell wall is typi-
cally considered a layered structure. Glucans and chitin, 
the main structural components that supply rigidity to 
the overall wall structure, appears to be more concen-
trated in the inner cell wall layer adjacent to the plasma 
membrane, whereas mannoproteins are present through 
the entire wall and are particularly abundant at the most 
external cell wall layers [37], including at the surface 
Fig. 5 SEM images of biofilm formation of Candida albicans inhibited with AgNPs (a) and (c) biofilm formation without any treatment displaying 
(1) True hyphae and (2) Yeast, (b) and (d) show biofilm formation inhibited by AgNPs after 24 h treatment at 0.089 ppm with inhibition of growth, 
scarce hyphae showing a disrupted and rough outer CW (as indicated by black arrows) in (3) disruption on the outer CW
Fig. 6 Preformed biofilm of C. albicans treated with AgNPs. a Preformed biofilm and b preformed biofilm after 24 h treatment of AgNPs. Cells were 
incubated for 48 h and treatment with AgNPs was 0.48 ppm. Treated pre‑formed biofilm had almost no true hyphae, and was clearly reduced in 
number of cells, disruption of the cell‑wall is observed in treated pre‑formed biofilm
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which normally exhibits a fibrillar appearance [37]. As 
seen in Fig. 9a, b, untreated fungal cells show the distinc-
tive cell wall layers and cell membrane, but in treated 
cells with AgNPs the layers within the enlarged cell wall 
are difficult to distinguish.
As shown in Fig.  9d (TEM images) and Fig.  10 (SEM 
images) we found that the interaction of nanoparticles 
lead to disruption of the outer CW and subsequently 
produce permeabilization that let smaller AgNPs to get 
inside the yeast. These observations are consistent with 
those reported by another research group, which has 
previously described these holes and pits [20]. Overall, 
the AgNPs prepared here demonstrated potent activity 
against biofilms formed by C. albicans, one of the most 
common opportunistic human fungal pathogens. The 
anti-biofilm effects are via CW disruption; more pre-
cisely, they affected survival of both the yeast and the fila-
mentous forms of the fungus when forming a biofilm at 
an IC50 of 0.0089 ppm and also on a preformed biofilm at 
an IC50 of 0.48 ppm (Fig. 3a, b).
AgNPs exert activity against bacteria or fungi via the 
permeabilization of target cell membranes [38]. The 
active AgNPs caused severe morphological changes in 
the fungal cells manifested by disruption of the cell mem-
brane structure (Figs.  4b, 5d, 6b, 9d). This membrane 
damage was also supported by SEM images where we 
Fig. 7 SEM images of C. albicans Biofilm. a SEM micrograph of a pre‑formed biofilm without treatment and b preformed biofilm after AgNPs treat‑
ment (0.48 ppm) showing; 1 the EPS protecting the yeasts, 2 AgNPs on the EPS aggregating, 3 damage to the CW with no hyphal formation. AgNPs 
0.48 ppm are aggregated 24 h after incubation of the biofilm
Fig. 8 TEM images of planktonic C. albicans treated with AgNPs. a Yeast without treatment, b yeast with 24 h treatment with AgNPs (0.0089 ppm), 
Cells without treatment revealed well‑conserved morphological features, with a distinctive cell‑wall and cytoplasmic membrane. After treatment 
with AgNPs enlargement of CW width was evident
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observed rough membranes (Fig. 4b) and on TEM images 
we observed changes in diameter and the structure on 
the outer and inner membrane (Figs. 8b, 9c, d).
Although the chemical arrangement of the mamma-
lian, bacterial and fungal external membranes diverge 
to a great degree, their membrane main structures are 
formed by the phospholipids that contain a negatively 
charged phosphate group [39] incorporated in the hydro-
philic head [40], which could be targeted by membrane-
disturbing cationic AgNPs [17].
The cytotoxicity of AgNPs on HePG2 cell lines was 
investigated (Fig. 3c). AgNPs were not cytotoxic to these 
human cells at concentrations that were effective against 
C. albicans biofilm formation and pre-formed biofilms, 
thus indicating that their membrane-damaging activity 
might not target mammalian phospholipids and mem-
branes at fungicidal concentrations.
The active positively-charged AgNPs not only could 
inhibit the growth of the planktonic form of the fungi, but 
also were able to prevent the growth and the subsequent 
activity of the hyphal form in an in vitro coculture model. 
This indicates that with proper formulation that helps 
to maintain the activity of the AgNPs might be effective 
drugs for the treatment or prevention of candidiasis.
The measurement of CW width was tested with TEM 
images of 100 yeast cells. The mean and standard devi-
ation of the control CW width were estimated to be 
105   ±   13  nm, those measurements for yeasts treated 
with AgNPs 0.0089  ppm were 206   ±   11  nm, p values 
were statistically significant at <0.05.
Fig. 9 TEM images of the CW of C. albicans. a, b images show yeast without treatment, 3 outer mannoproteins fibrillar layer, 2 inner cell wall layers 
with preponderance of Glucans and Chitin, 1 plasma membrane. Treated yeast with AgNPs are shown in (b) and (d) with swollen CW and loose 
of CW characteristic layers. Also in d the red arrow indicates an entrance (pore or hole), with nanoparticles crossing the cell wall and reaching the 
plasma membrane after 24 h incubation and treatment with AgNPs 0.48 ppm
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Conclusions
By utilizing microwave-assisted techniques [25] to produce 
AgNPs we eliminated the requirement of additional reduc-
tors, consequently excluding further contamination sources. 
With this methodology, we obtained clean AgNPs with-
out contaminants for biological tests [26]. With advanced 
electron microscopy methods we were able to observe that 
these positively-charged AgNPs disrupt the cell membrane, 
permeabilizing the outer CW as it becomes rough and dis-
tended, changing the CW width due permeabilization that 
let smaller AgNPs enter the cell. AgNPs were very effec-
tive inhibiting biofilm formation by disrupting the CW and 
inhibiting filamentation of the yeast. Also AgNPs were effec-
tive against a pre-formed biofilm in a dose response manner 
at a non-cytotoxic range. The observations on the inhibition 
of biofilm are supported by a phenotypic assay [34].
Methods
Chemicals and materials
Silver nitrate, AgNO3 (99.99  % purity), was obtained 
from Sigma-Aldrich Corporation (St. Louis, MO, USA) 
and utilized without further purification. Distilled water 
was purified using Whatman® 0.2 µm filters.
Preparation of AgNPs
AgNPs were synthesized through a microwave (MW) 
induced reaction using an Ethos EZ Digestion System 
Microwave (Milestone, 2.5 GHz, sensor ATC400) equip-
ment [25, 26]. Briefly, 1.7 g of AgNO3 was supplemented 
to 20  ml distilled H2O and introduced in the MW. The 
solution was continuously irradiated for 15 s at 1000 W. 
As a result we obtained a clear light yellow solution, dem-
onstrating the synthesis of AgNPs. We tested the solu-
tion by ICP spectroscopy obtaining a concentration of 
23,000  ppm of silver. The AgNPs were kept in the dark 
at room temperature to prevent aggregation. Ten micro-
liters of the AgNPs were located on Carbon-coated Cu 
grids  (300-mesh) for further characterization. It is well 
known that silver nitrate decompose into metallic silver, 
NO2 gas and O2 by the action of heat from the MW-irra-
diation, as represented in the Scheme 1 [41].
Thermal decomposition of silver cations is reduced to 
metallic silver nanoparticles, yielding NO2 gas as a major 
product. Qualitatively, thermal decomposition is minor 
below the melting point, but becomes significant around 
250 °C and totally decomposes at 440 °C.
Characterization of AgNPs
Electron microscopy characterization
AgNPs were characterized utilizing a high resolution TEM 
analyses 2010-F JEOL (JEOL  Inc, Tokyo, Japan) with a 
field emission gun operating at 200  kV. HAADF-STEM 
with resolution of 80 pm, one of the highest for a Cs cor-
rected TEM [36]. Fungal cell images were achieved uti-
lizing microscope in both bright-field (BF) and dark-field 
(DF) modes. The microscope was operating at 200 kV with 
a convergence angle of 26 mrad and collection semi angles 
between 50 and 180 mrad to obtain atomic scale imaging. 
The probe size used was approximately 0.0089 nm, and the 
probe current was 22 pA. Energy Dispersive-X-ray Spec-
troscopy (EDS) was performed using a solid state EDAX 
EDS detector to identify the AgNPs in the treated biofilm 
samples. A Hitachi 5500 SEM was used at 30 kV to collect 
SE images. The Zeta potential (ξ) measurement of AgNPs 
was determined by dynamic light scattering (DLS) using a 
Zetasizer NanoZS (Malvern Instruments, Worcestershire, 
UK) as previously described [42].
Strain, media and culture conditions
Candida albicans strain SC5314 (a clinical isolate 
originally obtained from a patient with disseminated 
Fig. 10 SEM images of treated planktonic yeast. a, b C. albicans 
treated with AgNPs, red arrows point at disruption on the outer CW 
after 24 h incubation and treatment with AgNPs 0.089 ppm
(1)
Scheme 1 Thermal decomposition of silver nitrate
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candidiasis) [43] was used in this study. For routine 
culture, cells from stocks stored at −80  °C were propa-
gated by streaking onto Yeast-peptone-dextrose (YPD) 
agar plates (1 % [wt/vol] yeast extract, 2 % [wt/vol] pep-
tone, 2 % [wt/vol] dextrose, 1.5 % agar), and incubation 
overnight at 30  °C. From these, a loopful of the over-
night  Candida  growth was inoculated into flasks con-
taining 25  ml of YPD liquid media in an orbital shaker 
at 180  rpm and 30  °C for 14–16  h. Under these condi-
tions, C. albicans grows as budding yeast. Biofilms were 
studied using the 96-well microtiter plate-based method 
previously reported by our group [34]. Briefly, cells har-
vested from overnight YPD cultures were washed and 
diluted in RPMI-1640 supplemented with l-glutamine 
(Corning-Cellgro) and buffered with 165 mM 3-(N-Mor-
pholino) propanesulfonic acid (MOPS, Sigma-Aldrich), 
with biofilms formed on flat-bottom 96 well  microplate 
(Corning Incorporated) following incubation at 37  °C 
for 24  h. After biofilm formation, the biofilm firmly 
attached to the wells were washed twice with phosphate-
buffered saline  (PBS) to eliminate non-adherent yeasts, 
and the quantity of biofilm formation determined using 
semi-quantitative colorimetric technique based on the 
reduction of 2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-
2H-tetra-zolium-5-carboxanilide salt (XTT, Sigma) as 
previously described by our group [34], with ODs deter-
mined spectrophotometrically utilizing a microtiter plate 
reader (Benchmark Microplate Reader; Bio-Rad Labora-
tories, Hercules, CA). The OD of control biofilms formed 
in the absence of AgNPs was arbitrarily set at 100 % and 
data was calculated as percent biofilm inhibition relative 
to the average of the control wells.
Inhibitory effects of AgNPs against C. albicans biofilms
AgNPs were evaluated for the inhibition of C. albicans 
biofilm formation, as well as for their fungicidal activ-
ity against pre-formed biofilms, at different concentra-
tions, ranging from 0.046 to 0.00036  ppm (for biofilm 
inhibition) and 1.38 to 0.003  ppm (for activity against 
pre-formed biofilms) in twofold dilutions as previ-
ously described [34]. Briefly, to evaluate the effect of 
the AgNPs in preventing biofilm formation, 50  μL 
of AgNPs diluted in RPMI media to appropriate con-
centrations were added to wells containing 50  μL of 
2  ×  106/mL C. albicans cells in a 96 microtiter well-
plate. To evaluate the efficacy of AgNPs against pre-
formed biofilms, wells were inoculated with 100 μL of 
1 × 106/mL C. albicans cells, the plates were incubated 
for 24 h and gently washed with PBS before 100 μL of 
different concentrations of AgNPs were added. After 
the addition of AgNPs, the 96 well-plates were cov-
ered with parafilm and incubated at 37  °C for 24  h. 
The plates were then washed twice with sterile PBS to 
remove non-adherent planktonic cells and processed 
using the tetrazolium salt (XTT) reduction assay to test 
the efficacy of the AgNPs preparations. All experiments 
were performed in duplicate and were repeated at least 
three times. The IC50 (defined as the concentration of 
AgNPs leading to 50 % inhibition) was calculated from 
the dose–response curves determined by fitting the 
data using Origin 8 (OriginLab Corp., Northampton, 
MA).
Cytotoxicity assay
Human hepatocellular carcinoma (HepG2) cells 
(ATCC#HB-8065) were used to determine the cytotoxic-
ity of AgNPs as in [44]. Briefly HepG2 cells were main-
tained in minimum essential medium (MEM, Gibco) 
enriched with 10  % fetal bovine serum (FBS), 1  mM 
sodium pyruvate (Gibco, Carlsbad, CA, USA), 1× MEM 
amino acid solution (Sigma-Aldrich), 100  IU  mL Peni-
cillin, and 100  mg streptomycin (Cellgro  Inc., Hern-
don, VA). At confluence monolayer-adhered cells were 
detached and dispersed using 1× Trypsin/EDTA solution 
(Gibco, Carlsbad, CA, USA). 5 × 105 cells/mL were added 
100 µL to each well of the 96-well microtiter plates con-
taining 100 µL of serial two-fold dilutions of the AgNPs. 
The 96 well plates were incubated for 24 h at 37 °C with 
CO2, and the cytotoxicity was determined using the 
PrestoBlue cell viability assay [45]. From these data, the 
CC50 value, defined as the concentration of AgNPs lead-
ing to 50 % inhibition. All experiments were performed 
in duplicate and were repeated for three times. The CC50 
was assessed from the dose–response curves determined 
by fitting the data using Origin 8 (OriginLab Corp., 
Northampton, MA).
Ultrastructural analysis of the interaction between AgNPs 
and planktonic C. albicans cells using TEM
A suspension of C. albicans cells (1.5 × 108 cells/ml) pre-
pared from yeast cultures grown for 24 h at 37 °C in YPD 
were mixed with AgNPs. The samples were then centri-
fuged for 10 min at 3500 rpm. The resultant pellets were 
each resuspended in 5  ml of PBS and spun down again 
for 10 min for washing. After washing two times, fixation 
of the fungal cells was performed by resuspending each 
pellet in 1  ml of 4  % formaldehyde and 1  % glutaralde-
hyde in PBS. After 2 h incubation at room temperature, 
the samples were stored at 4  °C until they were stained 
with 1 % osmium tetroxide (OsO4) at room temperature. 
After washing the Candida cells with PBS to eliminate 
excess OsO4, a dehydration series was performed with 25, 
50, 75, 95 and 100 % ethanol diluted in dH2O. The sam-
ples were additionally dehydrated with propylene oxide, 
embedded in a resin (LX112; Ladd Research Industry) 
and left to harden for 48  h at 60  °C. The resin capsules 
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were cut using an ultra microtome (Leica Ultracut, UCT) 
and a 45° diamond knife as previously described [42]. 
Ultrathin sections of approximately 95 nm were obtained 
and visualized using STEM mode in a JEM-ARM200F 
(JEOL USA Inc).
Cell wall width measurement (before and after treat-
ment with AgNPs) was performed by DigitalMicrograph 
(Gatan, Inc., Pleasanton, CA, USA). In this study, descrip-
tive statistics of CW width was conducted by deter-
mining mean and frequency distribution, Chi-square, 
ANOVA, Kruskal–Wallis and non parametric correlation 
using Origin 8 (OriginLab Corp., Northampton, MA). P 
value of less than 0.05 was considered significant.
Visualization of fungal planktonic cells and biofilms by SEM
For biofilm visualization by SEM, microtiter 96 well-
plates with C. albicans biofilms treated with AgNPs were 
washed with PBS and fixed with 4  % formaldehyde and 
1 % glutaraldehyde in PBS at room temperature. AgNPs 
were used at a concentration of 0.0089  ppm for inhibi-
tion of biofilm formation and at 0.48  ppm for activity 
against pre-formed biofilms. The samples were rinsed 
twice (3  min each) in 0.1  M phosphate buffer and then 
placed in 1 % osmium tetroxide (OsO4) for 1 h. The dry-
ing process of the samples was performed in a progres-
sive series of ethanol (30 % for 10 min, 50 % for 10 min, 
70 % for 10 min, 95 % for 10 min, and absolute alcohol for 
20 min). The specimens were then placed on copper grids 
to be observed with SEM in a Hitachi S-5500.
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